Advanced Search Close Search
BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model
Licensing Marketing Agreements

BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model

  • By BioLineRx Ltd., Hemispherian AS, BioLineRx Ltd.; Hemispherian AS

Synergy was demonstrated in a combination arm of GLIX1 and the PARP inhibitor olaparib at low doses, with substantially better efficacy compared to the control arm and compared to each drug individually at its optimal doseGLIX1 in combination with olaparib also showed comparable efficacy to that seen with the chemotherapy drug cisplatin Results reinforce synthetic lethality between GLIX1 and PARP inhibitors, indicating that GLIX1 can broaden the use of PARPi in ovarian cancerÂ